Issue link: https://www.e-digitaleditions.com/i/1546950
Inhalation OctOber 2026 21 Blister-strip filling for dry powder inhalers 3P innovation has created a rotary turret that gently compresses powder into small pockets on a contin- uously rotating disk. Doses are then cleanly ejected into a blister strip, ready for assembly into a device. Built with scalability in mind, the system is capable of high-speed commercial production, up to 7,200 doses per minute. It complies with critical quality attributes and has proven performance with magne- sium stearate-based powders. 3P innovation UK: +44 1926 408933 enquiries@3pinnovation.com www.3pinnovation.com A specialized excipient and range of inhalation-grade capsules Roquette's inhalation portfolio combines a special- ized excipient with a range of high-performance inhalation-grade capsules, and can ensure precision, stability and efficiency in dry powder inhalers (DPIs) and beyond. Our integrated approach can simplify formulation challenges, optimize powder flow and support both innovative and generic inhaled thera- pies. By leveraging deep expertise in excipients and inhalation- grade capsules, we provide a seamless solu- tion that can accelerate development, enhance for- mulation reliability and ensure compliance with the highest quality and regulatory standards, helping R&D teams bring effective inhalation therapies to market more efficiently. Roquette France pharma@roquette.com www.roquette.com Reformulating pressurized inhalers for low-GWP propellants e phase-out of high-GWP propellants is reshaping pMDI development. i2c Pharm works across pMDI, DPI, nasal and nebulized products from early feasi- bility to first-in-clinic supply. i2c Pharm has partic- ular depth in reformulating pressurized inhalers for next-generation propellants, including HFA-152a and HFO-1234ze(E), supported by the patented Respitab ® platform, which avoids ethanol co-solvents. Capabilities span formulation, analytical and aerosol characterization, alongside Fast2Clinic™ clinical-scale manufacturing. Integrated gamma scintigraphy and a 48-bed clinical research unit allow drug deposition and clearance to be assessed during development. i2c Pharm United Kingdom Andrew.Brown@i2cpharm.co.uk www.i2cpharm.co.uk

